1 | pharmacogenomics working group ipwg | | | | | | | 3 | 0.43% |
2 | industry pharmacogenomics working group | | | | | | | 3 | 0.43% |
3 | task forces and working | | | | | | | 3 | 0.43% |
4 | forces and working groups | | | | | | | 3 | 0.43% |
5 | in the field of | | | | | | | 3 | 0.43% |
6 | develop educational materials for | | | | | | | 2 | 0.29% |
7 | educational materials for investigators | | | | | | | 2 | 0.29% |
8 | materials for investigators and | | | | | | | 2 | 0.29% |
9 | for investigators and irbsiecs | | | | | | | 2 | 0.29% |
10 | investigators and irbsiecs in | | | | | | | 2 | 0.29% |
11 | and irbsiecs in order | | | | | | | 2 | 0.29% |
12 | optimize and streamline the | | | | | | | 2 | 0.29% |
13 | and streamline the implementation | | | | | | | 2 | 0.29% |
14 | streamline the implementation of | | | | | | | 2 | 0.29% |
15 | the implementation of pharmacogenomics | | | | | | | 2 | 0.29% |
16 | implementation of pharmacogenomics in | | | | | | | 2 | 0.29% |
17 | to optimize and streamline | | | | | | | 2 | 0.29% |
18 | well as operations we | | | | | | | 2 | 0.29% |
19 | areas of adme genetics | | | | | | | 2 | 0.29% |
20 | that a reader will | | | | | | | 2 | 0.29% |
21 | a reader will be | | | | | | | 2 | 0.29% |
22 | reader will be distracted | | | | | | | 2 | 0.29% |
23 | will be distracted by | | | | | | | 2 | 0.29% |
24 | be distracted by the | | | | | | | 2 | 0.29% |
25 | distracted by the readable | | | | | | | 2 | 0.29% |
26 | content of a page | | | | | | | 2 | 0.29% |
27 | when looking at its | | | | | | | 2 | 0.29% |
28 | looking at its layout | | | | | | | 2 | 0.29% |
29 | at its layout members | | | | | | | 2 | 0.29% |
30 | its layout members merck | | | | | | | 2 | 0.29% |
31 | layout members merck lilly | | | | | | | 2 | 0.29% |
32 | as well as operations | | | | | | | 2 | 0.29% |
33 | force was initiated to | | | | | | | 2 | 0.29% |
34 | in the areas of | | | | | | | 2 | 0.29% |
35 | research it does this | | | | | | | 2 | 0.29% |
36 | focused in the areas | | | | | | | 2 | 0.29% |
37 | of adme genetics regulatory | | | | | | | 2 | 0.29% |
38 | adme genetics regulatory science | | | | | | | 2 | 0.29% |
39 | working groups that are | | | | | | | 2 | 0.29% |
40 | and working groups that | | | | | | | 2 | 0.29% |